Table 4.

Subgroup summaries for levels associated with statistically significant interaction terms in the final reduced model

	Number	Overall population (%)	Switchers (%)
Fatigue at baselinea × DLQI at baselinea
Fatigue ≤ 18.6, DLQI ≤ 1.85	6934	50.3	3.8
Fatigue ≤ 18.6, DLQI > 1.85	1979	14.4	9.8
Fatigue > 18.6, DLQI ≤ 1.85	2473	18.0	6.6
Fatigue > 18.6, DLQI > 1.85	2386	17.3	12.8
NBSM added from baseline to follow-up × age at baselinea
NBSM added, age ≤ 53.2	40	0.3	42.5
NBSM added, age > 53.2	41	0.3	22.0
No NBSM added, age ≤ 53.2	6639	48.2	6.9
No NBSM added, age > 53.2	7052	51.2	6.3
PsA at baseline × age at baselinea
PsA, age ≤ 53.2	2593	18.8	9.4
PsA, age > 53.2	3353	24.3	7.4
No PsA, age ≤ 53.2	4086	29.7	5.7
No PsA, age > 53.2	3740	27.2	5.4
Gender at baseline × duration of biologic therapy at baseline
Male, 5 to < 12 months	2421	17.6	7.7
Male, 12 to < 24 months	2534	18.4	5.9
Male, ≥ 24 months	2509	18.2	4.1
Female, 5 to < 12 months	2276	16.5	10.0
Female, 12 to < 24 months	2145	15.6	6.2
Female, ≥ 24 months	1887	13.7	6.7
Gender at baseline × fatigue at baselinea
Male, fatigue ≤ 18.6	5234	38.0	5.1
Male, fatigue > 18.6	2230	16.2	7.7
Female, fatigue ≤ 18.6	3679	26.7	5.1
Female, fatigue > 18.6	2629	19.1	11.4
Employment at baseline × fatigue at baselinea
Full time, fatigue ≤ 18.6	5462	39.7	5.0
Full time, fatigue > 18.6	2710	19.7	10.0
Not full time, fatigue ≤ 18.6	3451	25.1	5.2
Not full time, fatigue > 18.6	2149	15.6	9.3
PsA at baseline × PGA at baselinea
PsA, PGA ≤ 15.1	4054	29.4	6.0
PsA, PGA > 15.1	1892	13.7	13.0
No PsA, PGA ≤ 15.1	6165	44.8	3.7
No PsA, PGA > 15.1	1661	12.1	12.2

DLQI Dermatology Life Quality Index, NBSM non-biologic systemic medication, PGA patient global assessment, PsA psoriatic arthritis

^aFor the continuous variables, the cutoff associated with each is equivalent to the overall mean in the population